Stock Taper
SCREENER COMPARE ANY 2 STOCKS
HROW
HARROW HEALTH, INC.
NASDAQ
$37.27
▼ DOWN 3.30% (-1.27)

KEY STATISTICS

Market Cap$1.39 B
52w High$54.85
52w Low$28.54
Dividend Yield—
Frequency—
P/E-37.65
Volume400.77K
Shares Out.37.28M

COMPANY

LEADERSHIP

Mark L. Baum
CHIEF EXECUTIVE
Mark L. Baum

COMPENSATION 2026

Salary$463,431
Stock Awards$0
Incentive Plan Pay$234,000
All Other Comp.$46,036
Total$743,467

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 28, 2007
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
373

PRICE TARGET

Target High$88.00
Target Low$63.00
Target Median$70.00
Target Consensus$73.67

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$98.74M
NOV
9
MON

SPLIT RECORD

DATETYPERATIO
2013-02-08Reverse1:5
2012-03-16Reverse1:8
2012-02-24Reverse1:8
2007-09-28Reverse231:500

PRICE

$37.27 ▼ DOWN 3.30% (−$1.27)
OVERLAYS
$37.50$38.259:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM37.27

About Harrow Health, Inc.

https://www.harrow.com ↗

Harrow Health, Inc. is an ophthalmology-focused healthcare company owning ImprimisRx, DEXYCU, and stakes in clinical-stage pharma firms, developing and commercializing ocular therapeutics and related products.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT HARROW HEALTH, INC. IS KNOWN FOR

VEVYE® (cyclosporine ophthalmic solution) 0.1%
VEVYE® (cyclosporine ophthalmic solution) 0.1%

VEVYE, launched in the U.S. in January 2024, is the first patented, non-preserved, twice-daily cyclosporine eye drop for dry eye disease, promoted with a money-back guarantee and patient access programs.

COMPETITORS

COMPETITOR
ABBV COMPARE
ALC COMPARE
BLCO COMPARE
OCUL COMPARE
VTRS COMPARE

Revenue by Products

IconPRODUCTQ1-2025Q2-2025Q1-2026Q2-2026
Product Sales Net— — $44.13M $70.57M ▲
Other Products$956K $5.21M ▲— —
Other Revenues— — $73K $90K ▲
Other Revenue$86K $85K ▼— —

ETFS HOLDING THIS STOCK

ETFS HOLDING
132
LISTED HERE
23
RANKED BY POSITION SIZE
VTI
0.00% · 1.0M
XSU.TO
0.04% · 831.1K
XPH
1.53% · 232.3K
SCHA
0.03% · 157.7K
DFAS
0.03% · 126.3K
PSC
0.14% · 103.8K
FYC
0.24% · 89.4K
FESM
0.05% · 78.7K
D5BM.DE
0.01% · 36.8K
GSSC
0.12% · 33.6K
AVSC
0.04% · 29.2K
XHYH
0.26% · 20.0K
RSSL
0.04% · 15.5K
BBSC
0.04% · 7.8K
PILL
1.03% · 6.5K
ETLZ.DE
0.07% · 3.9K
OMFS
0.04% · 3.0K
PQ
PQSG
0.21% · 3.0K
ACSG
0.10% · 1.3K
BIB
0.05% · 1.3K
QSML
0.14% · 451
EB
EBI
0.00% · 231
USFMDN.MX
0.00% · 154

INSTITUTIONAL OWNERSHIP

SHARES OWNED
49.97%
HOLDERS
306
TOP 12 OF 306 · RANKED BY POSITION SIZE
Opaleye Management Inc.
3.9M sh · $191.34M
Blackrock, Inc.
2.7M sh · $116.37M
Blackrock Inc.
2.1M sh · $44.88M
Vanguard Group Inc
1.9M sh · $94.16M
Private Capital Management, LLC
1.9M sh · $89.41M
Luxor Capital Group, LP
1.1M sh · $39.47M
Deep Track Capital, LP
969.0K sh · $41.15M
State Street Corp
939.9K sh · $39.92M
Geode Capital Management, LLC
905.6K sh · $38.47M
Bamco Inc /Ny/
809.4K sh · $34.37M
Dimensional Fund Advisors LP
667.0K sh · $28.33M
Marshall Wace, Llp
644.9K sh · $22.74M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF SCIENTIFIC OFFICER
Shojaei Amir
Purchase · 11.3K shares
2026-08-14
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Shojaei Amir
Sale · 11.3K shares
2026-08-14
★
DIRECTOR
Sternberg Perry J.
Purchase · 5.2K shares
2026-06-18
★
DIRECTOR
SILVERNAIL LAUREN P
Purchase · 5.2K shares
2026-06-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
OVERWEIGHT 1
7 GRADES IN THE LAST 12 MONTHS
BTIG BUY Cantor Fitzgerald OVERWEIGHT B. Riley Securities BUY HC Wainwright & Co. BUY Ladenburg Thalmann BUY Lake Street BUY Craig-Hallum BUY

SECTORS PEERS

PEERPRICE
TRVI$16.79COMPARE
BLFS$36.38COMPARE
ALVO$4.95COMPARE
KMTS$25.64COMPARE
AMPH$22.01COMPARE
COLL$25.35COMPARE
PHR$12.15COMPARE
EVO$1.91COMPARE